Close Menu

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Claudin-low breast cancer is a molecular subtype of breast cancer that is associated with poor survival. In this on-demand eCase Study video, Jim Hayes, a field application scientist at Qiagen, discusses an analysis workflow to search for putatively functional variants in claudin-low breast cancer cell lines by comparing them to luminal breast cancer cell lines.

The presentation outlines a filtering strategy to identify true, rare, homozygous variants in claudin-low cell lines for functional follow-up in the lab.

Sponsored by

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Apr
28
Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.